DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans.

Author(s): Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, Haas R

Affiliation(s): Department of Haematology, Oncology and Clinical Immunology, Heinrich Heine-University, Dusseldorf, Germany. fabian.zohren@med.uni-duesseldorf.de

Publication date & source: 2008-04-01, Blood., 111(7):3893-5. Epub 2008 Jan 30.

Publication type: Clinical Trial

We investigated the role of adhesion molecule VLA-4 in CD34+ blood stem-cell mobilization. Therefore, we examined 20 patients with multiple sclerosis (MS) who were treated with the anti-VLA-4 antibody natalizumab. Treated patients had received a median number of 4 natalizumab infusions (range: 2-9 infusions). Blood samples were taken 4 weeks following the last infusion. With a median proportion of 7.6 CD34+ cells/microL (range: 2.2-30.4 cells/microL), these patients had a significantly higher (P=.003) amount of circulating CD34+ cells compared with 5 healthy volunteers (median: 1.4/microL; range: 0.6-2.4/microL) and 5 untreated MS patients (median: 1.0/microL; range: 0.5-1.7/microL) (P=.001). Serial measurements in 4 patients receiving their first natalizumab infusion showed a maximal significant increase in circulating CD34+ cells from 3.3/microL (range: 1.6-4.8/microL) to 10.4/microL (range: 7.5-12.04/microL) 72 hours following natalizumab infusion (P=.001), including pluripotent cells in colony-forming assays. This mobilizing ability of natalizumab might be useful for patients with poor response to granulocyte colony-stimulating factor (G-CSF)-based protocols.

Page last updated: 2008-08-10

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017